AOP Health Starts Research for Leukemia Treatment

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.

Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group

Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.

Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech

Copyright: Albert Mollon

Agreement sets basis for new areas of therapy

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

Development in cooperation with Leukos

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

About Leukos

Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.

About the Josep Carreras Foundation

The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus

About Inveready

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

AOP Health commence la recherche d’un traitement pour la leucémie

AOP Health a signé un accord avec Leukos Biotech pour la poursuite du développement d’une substance chimique récemment découverte. Avec cet accord, AOP Health élargit encore davantage le domaine de la recherche sur l’hémato-oncologie et propose des options de traitement supplémentaires à certains patients atteints de leucémie sur le long terme.

VIENNE, Autriche, 01 août 2022 (GLOBE NEWSWIRE) — AOP Health Group (AOP Health) est un pionnier européen des thérapies intégrées pour les maladies rares et les soins intensifs basé à Vienne, en Autriche. La société se concentre sur la recherche, le développement et la vente mondiale de solutions de traitement innovantes et se spécialise dans les thérapies pour les maladies rares et les soins intensifs. Début juillet, AOP Health a signé un accord avec Leukos Biotech, une société dérivée fondée par l’institut de recherche sur la leucémie Josep Carreras, basé à Barcelone. L’accord signé par AOP Health couvre l’option de développement de la substance chimique récemment découverte dans le cadre de toute indication traitable, non limitée aux maladies oncologiques ou rares.

L’accord établit la base de nouveaux domaines thérapeutiques

Dans un premier temps, AOP Health se concentrera sur le développement d’options de traitement pour la leucémie myéloïde aiguë (LMA) et le syndrome myélodysplasique (SMD). Les deux sont des types particuliers de leucémie qui commencent souvent dans la moelle osseuse. Agnes Kohl, directrice commerciale d’AOP Orphan Pharmaceuticals GmbH, membre du groupe AOP Health, explique : « Sur la base de données positives, notre plan est d’étendre le développement d’autres indications orphelines même en dehors de la LMA et du SMD à un stade ultérieur. Grâce à cet accord, nous pourrons peut-être élargir le portefeuille de nos domaines thérapeutiques en offrant encore plus d’options de traitement aux patients. »

Développement en coopération avec Leukos

Comme AOP Health se concentre sur les cancers hémato-oncologiques rares et possède de nombreuses années d’expérience dans le développement et la commercialisation de traitements hémato-oncologiques, la société pilotera le développement ultérieur de la substance en coopération avec Leukos sur la base d’un nouveau mode d’action. Cela pourrait potentiellement devenir une étape importante dans le traitement de nombreux cancers du sang et autres patients atteints de cancer. Luis Ruiz-Avila, PDG de Leukos Biotech : « Nous nous concentrons sur le développement de nouveaux traitements pour une grande variété de tumeurs. Nous sommes nés pour transformer l’excellente science de l’Institut de recherche sur la leucémie Josep Carreras en produits précieux pour les patients atteints de cancer dans le besoin, et cet accord est une étape très importante dans cette direction. Nous sommes convaincus qu’AOP Health est le bon partenaire pour transformer ce nouveau mécanisme d’action prometteur en une réalité clinique au profit des patients présentant une grande variété de besoins médicaux non satisfaits. »

À propos d’AOP Health

Le groupe AOP Health comprend plusieurs sociétés, dont AOP Orphan Pharmaceuticals GmbH, dont le siège se trouve à Vienne, en Autriche (« AOP Health »). Le groupe AOP Health est le pionnier européen des thérapies intégrées pour les maladies rares et les soins critiques. Au cours des 25 dernières années, le groupe est devenu un fournisseur établi de solutions de thérapie intégrées opérant depuis son siège social à Vienne, ses filiales et ses bureaux de représentation à travers l’Europe et le Moyen-Orient, ainsi que par l’intermédiaire de partenaires dans le monde entier. Ce développement a été rendu possible par un niveau d’investissement continu élevé dans la recherche et le développement, d’une part, et par une orientation très cohérente et pragmatique vis-à-vis des besoins de toutes ses parties prenantes, d’autre part, en particulier les patients et leurs familles, ainsi que les professionnels de la santé qui les prennent en charge.

À propos de Leukos

Leukos Biotech, SL (Leukos) est une société dérivée de l’Institut de recherche sur la leucémie Josep Carreras, créée à Barcelone en 2015. La société développe de nouveaux traitements et outils de diagnostic pour une large variété de tumeurs ciblant le récepteur de la sérotonine HTR1B, dont le potentiel antitumoral a été décrit pour la première fois et breveté par le Dr Ruth Risueño, fondateur de Leukos dans son laboratoire à l’Institut de recherche Josep Carreras. Le principal soutien financier de Leukos provient d’investisseurs privés et institutionnels. Les principaux actionnaires sont Inveready, CDTI Innvierte et la Fondation Josep Carreras. Outre le soutien des investisseurs, Leukos a reçu des subventions et des prêts non dilutifs du gouvernement catalan, du gouvernement espagnol et de l’Union européenne dans le cadre de divers programmes.

À propos de la Fondation Josep Carreras

La Fondation Josep Carreras Leukaemia a été créée en 1988 dans le but de contribuer à la recherche d’un remède définitif pour cette maladie. Ses efforts se concentrent sur quatre domaines fondamentaux : l’administration du Registre espagnol de donneurs de moelle osseuse (REDMO), la recherche scientifique menée par l’Institut de recherche sur la leucémie Josep Carreras, l’orientation des patients via un canal de consultation des patients en ligne et des appartements d’accueil pour les patients qui ont besoin de subir un traitement et doivent passer beaucoup de temps loin de chez eux.

À propos de l’Institut de recherche sur la leucémie Josep Carreras

L’Institut de recherche sur la leucémie Josep Carreras, centre public appartenant au réseau CERCA de la Generalitat de Catalunya, a été créé en 2010 dans le but de promouvoir la recherche biomédicale et la médecine personnalisée dans le domaine de la leucémie et d’autres maladies onco-hématologiques. Il s’agit du premier centre de recherche européen exclusivement dédié à la leucémie et aux hémopathies malignes, et l’un des rares au monde. Les Instituts Josep Carreras disposent de trois campus scientifiques coordonnés mais indépendants : le Campus clinique de l’Hôpital de l’Université de Barcelone, le Campus de l’Institut catalan d’oncologie/allemands Trias i Pujol et le Campus de Sant Pau – Autonomous University of Barcelona (UAB).

À propos d’Inveready

Inveready est un gestionnaire d’actifs alternatifs de premier plan en Espagne ; il investit dans le capital-risque en phase de démarrage, le capital-risque de croissance, la dette à risque, les actions stratégiques dans des sociétés cotées, les infrastructures et le capital-investissement privé. Il fournit des solutions de financement aux entreprises tout au long de leur cycle de vie. Fondée en 2008, Inveready compte sur 200 sociétés actives et plus d’un milliard d’euros d’actifs sous gestion. Inveready investit dans des entreprises du secteur des sciences de la vie depuis 2008. Les investissements notables dans ce secteur sont Atrys Health (cotée sur le marché espagnol), EDESA Biotech (cotée au Nasdaq), AVX Pharma (vendue à Aerie Biotech) et PaloBiofarma (accord de licence avec Novartis). Le siège social de la société se situe à San Sebastian et elle possède d’autres bureaux à Barcelone et Madrid. La société a été reconnue à plusieurs reprises par l’ASCRI et Preqin pour le rendement de ses fonds et de ses transactions (Pour plus d’informations, veuillez consulter le site www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Besoins. Science. Confiance.

AOP Orphan Pharmaceuticals GmbH
Membre du groupe AOP Health

Leopold-Ungar-Platz 2, 1190 Vienne, Autriche
aop-health.com

Des photographies accompagnant ce communiqué sont disponibles aux adresses :

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease  

WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.

“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Eskom meets with business, JSE

Eskom has met with Chief Executive Officers (CEOs) and top leadership from at least 70 businesses n a Johannesburg Stock Exchange (JSE) and Business Leadership South Africa (BLSA)-led session.

The session is part of the state power utility’s efforts to find solutions to its ailing power generation issues.

During the session Eskom CEO André de Ruyter mapped out the strategies currently in place to ensure that there is enough power supply on the grid.

“The purpose of the discussions was to identify initiatives where the parties can collaborate and plant the seeds of opportunity to leverage private sector investment capacity and harvest the low hanging fruit in the electricity industry,” de Ruyter said.

The Eskom CEO called on the business leaders to support the power utility’s electricity strategy by “pursuing opportunities to make investments and realising savings benefits from the reforms of the electricity industry” that were announced by President Cyril Ramaphosa recently.

Group CEO of the JSE, Leila Fourie, highlighted the importance of private business and government working together to make sure that the electricity crisis is addressed.

“We are at a very important inflection point as a country and today we took the opportunity to unpack some of the proposed solutions for business-to-business partnerships in the generation of electricity. President Ramaphosa’s plan literally opens the door for investors and entrepreneurs to provide solutions that can have many other indirect and positive consequences for our country, especially when it comes to creating jobs.

“We need to work together to address the energy generation challenge to the benefit of all South Africans,” Fourie said.

According to Eskom, the session identified four areas where private business can make an impact including:

• Opportunities to invest in own-generation projects and Independent Power Producers (IPPs) through land leasing and wheeling arrangements

• Encourage the use of electricity sparingly to safeguard the national grid through co-ordinated energy efficiency campaigns

• Provide support for security interventions to protect the electricity infrastructure from vandalism and theft

• Contribute to the development and alignment of enabling policies related to the fiscus and environmental, energy and industrial sectors

“During a robust Question-and-Answer session, company CEOs expressed their appreciation of Eskom’s transparency on the key issues, offered practical solutions to unlock generation capacity and pledged their support of the public utility’s plan in partnership with the relevant government role players. Through BLSA, a framework for delivery will be tabled with companies to ensure traction on the agreed initiatives.

“The parties have committed to extending the discussions to stakeholders based in both Cape Town and Durban, where some of the large electricity users and potential electricity investors are based,” Eskom said.

Source: South African Government News Agency

Brutal Gang Rape Shocks South Africa

A South African court on Monday began proceedings against more than 80 people arrested after the brazen gang rape of eight women. The women were filming a music video last week when they were attacked by masked, armed men.

Women’s rights activists protested outside the Krugersdorp Magistrate’s Court against the high rates of gender violence in South Africa as dozens of men detained in sweeping arrests in the aftermath of the incident were set to appear in court.

No one has yet been charged with rape and police investigations into the incident are continuing.

Eight women were raped and robbed while shooting a video in the mining area of Krugersdorp outside Johannesburg last Thursday, Police Ministry spokeswoman Lirandzu Themba told VOA.

They were approached by men wearing balaclavas and firing guns in the air and raped multiple times.

“On Sunday the police minister Bheki Cele met six of the eight survivors of the gang rape that has shocked the country,” said Themba.

The youngest of the women was just 19, Cele said after the meeting. “Let me tell you, they’re quite traumatized. They’re not in a good shape, mentally or otherwise.”

Local media reported that many of those arrested were believed to be illegal miners, known here as zama-zamas, and that some had also been arrested for being illegal immigrants from neighboring countries. Two suspects were killed during the shootout with police last Thursday.

The more than 80 men have now been charged with contravention of the immigration act and possession of stolen goods, police said.

It was unclear how many, if any, of them were connected directly to the gang rapes, Cele said, adding that forensic testing was pending. “Many people have been arrested but we need the real perpetrators among those people,” said Cele.

Women’s Month

South Africa is celebrating Women’s Month through August.

Shenilla Mohamed, executive director of Amnesty International South Africa, said the rights group was “outraged” by the gang rapes.

“It is unacceptable that woman and children in South Africa are still unsafe due to the high levels of domestic and sexual violence. Authorities must do much more to ensure that South Africa becomes a safer place for women and children and that they do not live in fear,” said Mohamed.

Despite having a very high rate of rape and gender-based violence, the brutal attack has shocked South Africa, which begins celebrating Women's Month from Monday.

More than 36,000 cases of rape were recorded in the country in the financial year 2020 – 2021.

Source: Voice of America

Government is committed to ensuring energy security

Minister in the Presidency, Mondli Gungubele, says government is focused on improving the performance of Eskom’s power stations and “adding as much new generation capacity to the grid as possible, as quickly as possible” in order to ensure energy security.

He was speaking during a media briefing by several ministers whose departments fall under the National Energy Crisis Committee (NECOM).

The NECOM – which comprises of Eskom and relevant government departments – was announced by President Cyril Ramaphosa during an address to the nation last Monday on interventions to address the electricity crunch the country has been experiencing.

NECOM will report to an inter-ministerial committee chaired by the President and comprises of Minister Gungubele, Minister of Mineral Resources and Energy, Gwede Mantashe; Minister of Public Enterprises, Pravin Gordhan; Minister of Finance, Enoch Godongwana; Minister of Forestry, Fisheries and the Environment ,Barbara Creecy; as well as the Minister of Trade, Industry and Competition Ebrahim Patel.

Gungubele told the briefing that government is proactively addressing energy concerns.

“Government is taking bold steps both to address the immediate crisis and to make load shedding a thing of the past. Further, we are mobilising all of the resources at our disposal and will do whatever it takes to achieve energy security.

“I must emphasise that achieving energy security is our single most important objective as a country, to enable economic growth and job creation. Our short-term objective is to reduce the severity and frequency of load shedding through immediate measures to stabilise the energy system. Our long-term objective is to end load shedding altogether,” Gungubele said at Monday’s briefing.

The minister highlighted that government has already taken steps in addressing energy shortages including:

• Changes have been made to the Regulations on New Generation Capacity to allow Municipalities to procure power independently. As a result, several municipalities are in the process of procuring additional power.

• A revival of the renewable energy procurement programme which enabled 2205 MW from Bid Window 4 to proceed to construction, the majority of which has now been connected to the grid.

• A further 6800 MW of solar PV and wind power is being procured in terms of the current Ministerial determination. This additional generation capacity will connect to the grid from late 2023. Another 3000 MW of gas and 513 of battery storage will be procured through the next bid windows.

• In 2021, the licensing threshold for power generations increased from 1MW to 100MW which has resulted in a pipeline of more than 80 confirmed private sector projects under development with a combined capacity of over 6000 MW, several of which will commence construction this year.

• Eskom has established an independent transmission company and is on track to separate its generation and distribution businesses by the end of 2022.

“These are just a few examples of the interventions government has already put in place. However, we recognise that we need to be responsive to the situation as it develops. The severe load shedding which we experienced last month showed that additional actions are necessary to restore system stability and increase generation capacity,” Gungubele said.

These actions will be guided by the five interventions outlined by President Ramaphosa, which are to:

• Fix Eskom and improve the availability of existing supply

• Enable and accelerate private investment in generation capacity

• Accelerate procurement of new capacity from renewables, gas and battery storage

• Unleash businesses and households to invest in rooftop solar

• Fundamentally transform the electricity sector to achieve long-term energy security.

“The NECOM has already begun to meet regularly to ensure that these actions are implemented swiftly. Eight work streams have been established to ensure coordination across government, and discussions are underway with the private sector and other social partners to ensure that the best available expertise in the country is brought into this effort.

“As the President said in his address to the nation: “The crisis that we are facing requires that we should take bold, courageous and decisive action to close the electricity gap. That is our overriding objective as government,” Gungubele said.

Source: South African Government News Agency

Women critical to ensuring objectives of ERRP are met

Frank conversations need to be had on the socio-economic empowerment and advancement of women, young women, and women with disabilities in South Africa, says Minister in the Presidency for Women, Youth and Persons with Disabilities, Maite Nkoana-Mashabane.

“At the heart of our mandate as the department is to ensure that women, youth and persons with disabilities play an effective role in representation, ownership and control of income generating assets within the economy.

“We must view their participation as critical to ensuring the objectives of the Economic Recovery and Reconstruction Plan are met.”

The Minister said this as she officially launched Women’s Month 2022 in KwaZulu-Natal on Monday, under the theme: Women’s Socio-Economic Rights and Empowerment: Building Back Better for Women’s Resilience.

The National Women’s Month programme is based on the ongoing interventions across the work of government, civil society and the private sector within the context of the national priorities outlined by government.

During her address to guests at a Women in Waste Management workshop, the Minister said the strategic focus of this year’s theme is to advance women’s socio-economic empowerment agenda towards the achievement of gender equality by 2030.

She said the recent floods in KwaZulu-Natal and Eastern Cape paint a devastating picture on the effects of choosing to ignore climate change.

“Now, more than ever, the green economy provides the necessary sustainable frameworks in which we can rebuild our economy in an inclusive manner. We must explore the economic, social and environmental potential of the green economy in driving gender equality.”

The Minister said 28 years into democracy women still remain on the periphery of the country’s developmental agenda.

“The COVID-19 pandemic has deepened existing inequalities leaving millions of women at the receiving end of high levels of poverty, increasing food and fuel prices, climate change, unemployment and high rates of gender-based violence and femicide (GBVF).

“We find ourselves in a moment of crisis where we need to act collectively to defend the democratic gains that the women of 1956 have worked so hard to achieve.”

Last week, young women in Krugersdorp were violated and raped while shooting a music video. “Unemployment is high in South Africa and to hear that these young women were approached by a group of men who raped and robbed them of their belongings is despicable.

“We are thankful of the interventions by SAPS on the apprehension of suspects and we hope that there will be convictions soon. We are also thankful as the young women are receiving psychosocial support for them and their families to overcome this ordeal,” said the Minister.

Source: South African Government News Agency